Welcome to the team, Delphine Sartiaux โ our new Fundraising & Development Manager!
Delphine brings rich experience in fundraising, strategic partnerships & international stakeholder engagement across global health NGOs.
Delighted to have her on board ๐
On #WorldMSDay, our President Jan Van Amstel shares why today must be a day of purpose.
In MS, time lost too often means function lost. Diagnosis is only the start; timely access must follow.โถ๏ธ Watch below ๐งก
@MSIntFederation@Lili_Bxl@annarevillab@eumsyouth
Progress on a new MS therapy โ shaped by the people it's for.
At IMMUTOL's 3rd Annual Meeting in Siena ๐ฎ๐น, EMSP brought expert patients Rebecca Maguire & @annarevillab into the room as the consortium advanced its vitamin D3 dendritic cell therapy for MS. #Immutol
Two days. 120+ participants. One shared conversation.
#EMSP2026 brought patients and experts to the same table-sharing research, naming gaps, shaping policy.
Thanks to @Roche and @sanofi for helping bring it to life and to everyone who showed up.
See you in Portugal.โ๏ธ #EMSP2027
๐ RiMS 2026 | 11โ13 June | Prague
The leading European gathering on MS rehabilitation โ from neuroplasticity to real-world outcomes that matter most for people with MS.
Highlight: "Coping with MS" panel, chaired by EMSP CEO @Lili_Bxl .
๐ https://t.co/srGchY2fEW #RiMS2026
516 patients per nurse.
That's the average caseload uncovered by our survey of 108 MS nurses across 15 countries.
Clinical trials, psychological support and benefits advice routinely left undone
Systemic change is overdue #InternationalNursesDay
Learm more https://t.co/WTjPg6mlXX
1.2M people live with MS in Europe and access to treatment still depends on where you live.
This May, our members @DMSG_BV ๐ฉ๐ช & @MSIRELAND ๐ฎ๐ช are taking on #TheMay50K, led by @MSIntFederation
Every kilometre moves research and equity forward.
Register- https://t.co/DwgRXrz3fI
1/ Final day of European Public Health Week ๐ช๐บ โ today's theme: the healthcare workforce.
Specialised MS nurses are the backbone of modern MS care. Without them, no therapy reaches its full potential. ๐งต
1/ It's European Public Health Week ๐ช๐บ โ today's theme: disinformation.
For people living with MS, NMOSD, and MOGAD, sorting fact from fiction online is a daily challenge. Misinformation isn't just confusing โ it can be harmful. ๐งต
#EUPHW
๐ ๐๐ก๐๐ญ ๐๐ก๐๐ฅ๐ฅ๐๐ง๐ ๐๐ฌ ๐ซ๐๐ฆ๐๐ข๐ง ๐ข๐ง ๐๐ข๐๐ ๐ง๐จ๐ฌ๐ข๐ง๐ ๐๐๐๐๐? Our latest Spotlight, ๐๐๐๐๐: ๐๐ฎ๐ฆ๐ณ๐จ๐ช๐ฏ๐จ ๐๐ฏ๐ด๐ช๐จ๐ฉ๐ต๐ด ๐ข๐ฏ๐ฅ ๐๐ท๐ฐ๐ญ๐ท๐ช๐ฏ๐จ ๐๐ฉ๐ข๐ญ๐ญ๐ฆ๐ฏ๐จ๐ฆ๐ด, explores the latest developments in MOGAD diagnosis, biomarkers, and therapeutic approaches.
Read the Spotlight here: https://t.co/OwPvVqNhSi
"While the criteria are a big step forward, obstacles remain in differentiating MOGAD from MS, which is crucial given the differences in treatment," says Professor Anne-Katrin Prรถbstel of Universitรคtsklinikum Bonn and Universitรคtsspital Basel (USB).
"A key unresolved question in MOGAD management is: how long do we treat people for, both after an initial attack and in those who experience relapses?" adds Dr. Wei Yeh of Monash University in Melbourne.
The ECTRIMS Spotlight Series is curated and authored by our Scientific Content Writer, Stefania de Vito.
#MultipleSclerosis #MOGAD #MSResearch #Neurology #MSSpotlight #Neuroimmunology #ECTRIMS